Myriad Genetics Talks with UnitedHealthcare on Insurance Exclusion Might Extend Into 2025

Dow Jones2024-12-11

By Sabela Ojea

Myriad Genetics might not be able to ensure a change in the updated medical policy of UnitedHealthcare after the company announced it would restrict access to multi-gene panel tests for behavioral-health diagnoses beginning Jan. 1.

The genetic testing and precision medicine company on Tuesday said that, while it wishes to reach a positive resolution before the end of the year, discussions with the health insurance company may extend into early 2025.

"Following the tragic death of UnitedHealthcare CEO Brian Thompson on Dec. 4, we extend our deepest condolences to Brian's family and all employees of UnitedHealthcare. Soon, at the appropriate time, we plan to continue our dialogue with UNH and other key stakeholders," Myriad Genetics Chief Executive Paul Diaz said.

Myriad has requested that UHC enrollees continue to have access to its GeneSight test in 2025, especially in the primary care setting where a significant majority of antidepressants are prescribed, the company said.

The news comes about two months after the UnitedHealth Group unit said it planned to discontinue coverage and remove prior authorization requirements for multi-panel pharmacogenetic codes, it said.

Shortly after that, on Nov. 4, Myriad said it strongly disagreed with UnitedHealthcare's inclusion of GeneSight and was in talks with the unit for it to reverse its decision.

Write to Sabela Ojea at sabela.ojea@wsj.com

(END) Dow Jones Newswires

December 10, 2024 19:01 ET (00:01 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2490572076?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-11 08:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2490572076","market":"sh","top_or_hot":-1,"title":"Myriad Genetics Talks with UnitedHealthcare on Insurance Exclusion Might Extend Into 2025","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Sabela Ojea \n</p>\n<pre>\n \n</pre>\n<p>\n  Myriad Genetics might not be able to ensure a change in the updated medical policy of UnitedHealthcare after the company announced it would restrict access to multi-gene panel tests for behavioral-health diagnoses beginning Jan. 1. \n</p>\n<p>\n  The genetic testing and precision medicine company on Tuesday said that, while it wishes to reach a positive resolution before the end of the year, discussions with the health insurance company may extend into early 2025. \n</p>\n<p>\n  \"Following the tragic death of UnitedHealthcare CEO Brian Thompson on Dec. 4, we extend our deepest condolences to Brian's family and all employees of UnitedHealthcare. Soon, at the appropriate time, we plan to continue our dialogue with UNH and other key stakeholders,\" Myriad Genetics Chief Executive Paul Diaz said. \n</p>\n<p>\n  Myriad has requested that UHC enrollees continue to have access to its GeneSight test in 2025, especially in the primary care setting where a significant majority of antidepressants are prescribed, the company said. \n</p>\n<p>\n  The news comes about two months after the UnitedHealth Group unit said it planned to discontinue coverage and remove prior authorization requirements for multi-panel pharmacogenetic codes, it said. \n</p>\n<p>\n  Shortly after that, on Nov. 4, Myriad said it strongly disagreed with UnitedHealthcare's inclusion of GeneSight and was in talks with the unit for it to reverse its decision. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Sabela Ojea at sabela.ojea@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 10, 2024 19:01 ET (00:01 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Myriad Genetics Talks with UnitedHealthcare on Insurance Exclusion Might Extend Into 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMyriad Genetics Talks with UnitedHealthcare on Insurance Exclusion Might Extend Into 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-11 08:01 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Sabela Ojea \n\n\n \n\n\n  Myriad Genetics might not be able to ensure a change in the updated medical policy of UnitedHealthcare after the company announced it would restrict access to multi-gene panel ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1989771016.USD","symbol_name":"东方汇理环球老龄化投资基金 A2 Acc","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2490572076","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2490572076","pubTimestamp":1733875260,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Myriad Genetics might not be able to ensure a change in the updated medical policy of UnitedHealthcare after the company announced it would restrict access to multi-gene panel tests for behavioral-health diagnoses beginning Jan. 1.The genetic testing and precision medicine company on Tuesday said that, while it wishes to reach a positive resolution before the end of the year, discussions with the health insurance company may extend into early 2025.\"Following the tragic death of UnitedHealthcare CEO Brian Thompson on Dec. 4, we extend our deepest condolences to Brian's family and all employees of UnitedHealthcare. Soon, at the appropriate time, we plan to continue our dialogue with UNH and other key stakeholders,\" Myriad Genetics Chief Executive Paul Diaz said.Myriad has requested that UHC enrollees continue to have access to its GeneSight test in 2025, especially in the primary care setting where a significant majority of antidepressants are prescribed, the company said.The news comes ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","SG9999018865.SGD":"United Global Quality Growth Fd Cl Dist SGD-H","LU0128525929.USD":"TEMPLETON GLOBAL \"A\" (USD) ACC","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","LU2357305700.SGD":"Allianz Global Artificial Intelligence ET H2-SGD","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","LU1988902786.USD":"FULLERTON LUX FUNDS GLOBAL ABSOLUTE ALPHA \"I\" (USD) ACC","LU1119994496.HKD":"FIDELITY WORLD \"A\" (HKD) ACC","LU1506573853.SGD":"MANULIFE GF GLOBAL EQUITY \"AA\" (SGD) INC","BK4566":"资本集团","LU2244417387.USD":"FIDELITY SUSTAINABLE US EQUITY \"A\" (USD) ACC","LU1037948897.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (HKD) INC","LU2125154778.USD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (USD) INC","LU0310800379.SGD":"FTIF - Templeton Global A Acc SGD","LU1153585028.USD":"BGF GLOBAL LONG-HORIZON EQUITY  \"A4\" (USD) INC","LU0107464264.USD":"abrdn SICAV I - GLOBAL INNOVATION EQUITY \"A\" (USD) ACC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","BK4588":"碎股","LU2028103732.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AMG\" (USD) INC","LU1037948541.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (HKD) ACC","MYGN":"万基遗传","LU1261432733.SGD":"Fidelity World A-ACC-SGD","SG9999002232.USD":"Allianz Global High Payout USD","LU2362540622.SGD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (SGDHDG) ACC","LU2125154935.USD":"ALLSPRING (LUX) WF GLOBAL EQUITY ENHANCED INCOME \"I\" (USD) INC","LU1323610961.USD":"UBS (LUX) EQUITY SICAV - LONG TERM THEMES (USD) \"P\" (USD) ACC","IE0004445015.USD":"JANUS HENDERSON BALANCED \"A2\" (USD) ACC","LU0795875086.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD","LU2361044865.SGD":"WELLINGTON US QUALITY GROWTH \"A\" (SGDHDG) ACC","LU0211326755.USD":"TEMPLETON GLOBAL INCOME \"A\" (USD) ACC","LU0097036916.USD":"贝莱德美国增长A2 USD","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","LU1854103824.USD":"M&G (LUX) POSITIVE IMPACT \"A\" (USD) INC","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","LU0158827948.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"A\" (USD) INC","LU1674673691.USD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AD\" (USD) INC","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","LU2361045086.USD":"WELLINGTON US QUALITY GROWTH \"A\" (USD) ACC","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","LU2552382215.SGD":"WELLINGTON US BRAND POWER \"A\" (SGDHDG) ACC","LU0708994859.HKD":"TEMPLETON GLOBAL \"A\" (HKD) ACC","LU2552382058.USD":"WELLINGTON US BRAND POWER \"A\" (USD) ACC","LU0795875169.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD-H","SG9999014906.USD":"大华全球优质成长基金Acc USD","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","LU0345770993.USD":"NINETY ONE GSF GLOBAL STRATEGIC EQUITY \"A\" (USD) INC","LU1069347547.HKD":"AB SICAV I - GLOBAL VALUE PORTFOLIO \"AD\" (HKD) INC","LU0029864427.USD":"TEMPLETON GLOBAL \"A\" (USD) INC","UNH":"联合健康"},"translate_title":"Myriad Genetics与UnitedHealthcare关于保险排除的谈判可能会延长至2025年","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MYGN":1,"UNH":0.72},"content_text":"By Sabela Ojea \n\n\n \n\n\n  Myriad Genetics might not be able to ensure a change in the updated medical policy of UnitedHealthcare after the company announced it would restrict access to multi-gene panel tests for behavioral-health diagnoses beginning Jan. 1. \n\n\n  The genetic testing and precision medicine company on Tuesday said that, while it wishes to reach a positive resolution before the end of the year, discussions with the health insurance company may extend into early 2025. \n\n\n  \"Following the tragic death of UnitedHealthcare CEO Brian Thompson on Dec. 4, we extend our deepest condolences to Brian's family and all employees of UnitedHealthcare. Soon, at the appropriate time, we plan to continue our dialogue with UNH and other key stakeholders,\" Myriad Genetics Chief Executive Paul Diaz said. \n\n\n  Myriad has requested that UHC enrollees continue to have access to its GeneSight test in 2025, especially in the primary care setting where a significant majority of antidepressants are prescribed, the company said. \n\n\n  The news comes about two months after the UnitedHealth Group unit said it planned to discontinue coverage and remove prior authorization requirements for multi-panel pharmacogenetic codes, it said. \n\n\n  Shortly after that, on Nov. 4, Myriad said it strongly disagreed with UnitedHealthcare's inclusion of GeneSight and was in talks with the unit for it to reverse its decision. \n\n\n \n\n\n  Write to Sabela Ojea at sabela.ojea@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 10, 2024 19:01 ET (00:01 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.0","shortVersion":"4.30.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2490572076"}